GlassScriptPhysician profile
William M Duke
NPI 1740273549
$6,826.11
in general payments reported to CMS, 2019-2025
50 companies · $1,194 in 2025
The $1,194 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $899 · 2020: $440 · 2021: $992 · 2022: $1,097 · 2023: $1,028 · 2024: $1,176 · 2025: $1,194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,397.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,305.12 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $998.33 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $417.45 | 2021-2025 | Vraylar |
| Pfizer INC. | $399.89 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $391.58 | 2019-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $294.10 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $235.70 | 2019-2025 | Verquvo, Dificid, Gardasil |
| Novartis Pharmaceuticals Corporation | $227.83 | 2019-2024 | |
| Astellas Pharma US INC | $226.33 | 2019-2025 | Veozah |
| Novo Nordisk INC | $217.94 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $197.33 | 2021-2024 | |
| Amgen INC. | $165.26 | 2019-2025 | Otezla, Repatha, Repatha |
| Noven Therapeutics, LLC | $147.83 | 2024-2025 | Xelstrym |
| Amarin Pharma, INC. | $120.70 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $111.82 | 2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Duke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.